CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer Clinical Trial

Official title: Combination Therapy of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Status Recruiting

Clinical Trial Summary

The study is to assess the safety and efficacy of the immunotherapies using anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells in the treatment of patients with advanced esophageal cancer.

Clinical Trial Description

This is a combined phase 1 and 2 clinical study. The aim of the study is to assess the safety and efficacy of the immunotherapies using anti- MUC1 CAR T cells alone, anti- MUC1 CAR T combining PD-1 knockout engineered T cells, and PD-1 knockout engineered T cell only in the treatment of patients with advanced esophageal cancer. The treatment outcomes from each group will be compared. ;

Related Conditions & MeSH terms

• Advanced Esophageal Cancer
• Esophageal Neoplasms

• NCT number: NCT03706326
• Study type: Interventional
• Source: The First Affiliated Hospital of Guangdong Pharmaceutical University
• Contact: Size Chen, MD, PhD
• Phone: +8613720956393
• Email: 13720956393@139.com
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: September 28, 2018
• Completion date: September 28, 2021